The potential effects of DPP‐4 inhibitors on cardiovascular system in COVID‐19 patients
With the outbreak of a new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the public healthcare systems are facing great challenges. Coronavirus disease 2019 (COVID‐19) could develop into severe pneumonia, acute respiratory distress syndrome and multi‐organ failure. Remar...
Gespeichert in:
| Veröffentlicht in: | Journal of cellular and molecular medicine 2020-09, Vol.24 (18), p.10274-10278 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 10278 |
|---|---|
| container_issue | 18 |
| container_start_page | 10274 |
| container_title | Journal of cellular and molecular medicine |
| container_volume | 24 |
| creator | Du, Hengzhi Wang, Dao Wen Chen, Chen |
| description | With the outbreak of a new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the public healthcare systems are facing great challenges. Coronavirus disease 2019 (COVID‐19) could develop into severe pneumonia, acute respiratory distress syndrome and multi‐organ failure. Remarkably, in addition to the respiratory symptoms, some COVID‐19 patients also suffer from cardiovascular injuries. Dipeptidyl peptidase‐4 (DPP‐4) is a ubiquitous glycoprotein which could act both as a cell membrane‐bound protein and a soluble enzymatic protein after cleavage and release into the circulation. Despite angiotensin‐converting enzyme 2 (ACE2), the recently recognized receptor of SARS‐CoV and SARS‐CoV‐2, which facilitated their entries into the host, DPP‐4 has been identified as the receptor of middle east respiratory syndrome coronavirus (MERS‐CoV). In the current review, we discussed the potential roles of DPP‐4 in COVID‐19 and the possible effects of DPP‐4 inhibitors on cardiovascular system in patients with COVID‐19. |
| doi_str_mv | 10.1111/jcmm.15674 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7521316</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2773544746</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5044-7d2a8f52d6fc32b80efc53b92fd9197b806910779bf1a1385f3fb90b34f9a7d23</originalsourceid><addsrcrecordid>eNp9kbtuFDEUhi1EREKg4QGQJRqEtInvlwYJbbgkSpQUgYbC8nhs1quZ8caeCdqOR-AZeRK87CYCirixdfz5s49_AF5gdITrOF66vj_CXEj2CBxgrsiMacoe79ZYUbUPnpayRIgKTPUTsE-JxBQLfAC-Xi88XKXRD2O0HfQheDcWmAI8ubr69eMng3FYxCaOKdfqAJ3NbUy3tripsxmWdRl9Xxk4v_xyelIPYA1XdozVV56BvWC74p_v5kPw-cP76_mn2fnlx9P5u_OZ44ixmWyJVYGTVgRHSaOQD47TRpPQaqxlLQiNkZS6CdhiqnigodGooSxoWw_TQ_B2611NTe9bV-_OtjOrHHub1ybZaP7dGeLCfEu3RnKy-YYqeL0T5HQz-TKaPhbnu84OPk3FEEYkx1ohWdFX_6HLNOWhtmeIlJQzJpl4kGJMCKKEopV6s6VcTqVkH-6fjJHZJGs2yZo_yVb45d9N3qN3UVYAb4HvsfPrB1TmbH5xsZX-Bm0urvg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2446628683</pqid></control><display><type>article</type><title>The potential effects of DPP‐4 inhibitors on cardiovascular system in COVID‐19 patients</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><creator>Du, Hengzhi ; Wang, Dao Wen ; Chen, Chen</creator><creatorcontrib>Du, Hengzhi ; Wang, Dao Wen ; Chen, Chen</creatorcontrib><description>With the outbreak of a new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the public healthcare systems are facing great challenges. Coronavirus disease 2019 (COVID‐19) could develop into severe pneumonia, acute respiratory distress syndrome and multi‐organ failure. Remarkably, in addition to the respiratory symptoms, some COVID‐19 patients also suffer from cardiovascular injuries. Dipeptidyl peptidase‐4 (DPP‐4) is a ubiquitous glycoprotein which could act both as a cell membrane‐bound protein and a soluble enzymatic protein after cleavage and release into the circulation. Despite angiotensin‐converting enzyme 2 (ACE2), the recently recognized receptor of SARS‐CoV and SARS‐CoV‐2, which facilitated their entries into the host, DPP‐4 has been identified as the receptor of middle east respiratory syndrome coronavirus (MERS‐CoV). In the current review, we discussed the potential roles of DPP‐4 in COVID‐19 and the possible effects of DPP‐4 inhibitors on cardiovascular system in patients with COVID‐19.</description><identifier>ISSN: 1582-1838</identifier><identifier>ISSN: 1582-4934</identifier><identifier>EISSN: 1582-4934</identifier><identifier>DOI: 10.1111/jcmm.15674</identifier><identifier>PMID: 32713161</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>ACE2 ; Angiotensin ; Angiotensin-converting enzyme 2 ; Atherosclerosis ; Binding sites ; Cardiomyocytes ; Cardiovascular Diseases - enzymology ; Cardiovascular Diseases - virology ; Cardiovascular system ; Cell membranes ; Chemokines ; Coronaviridae ; Coronaviruses ; COVID-19 ; COVID-19 Drug Treatment ; Cytokines ; Diabetes ; Dipeptidyl Peptidase 4 - metabolism ; Dipeptidyl-peptidase IV ; Dipeptidyl-Peptidase IV Inhibitors - pharmacology ; DPP‐4 inhibitors ; Enzymes ; Glucagon ; Glycoproteins ; Growth factors ; Heart ; Homeostasis ; Hormones ; Host-Pathogen Interactions ; Humans ; Infections ; Inflammation ; Kinases ; Membrane proteins ; Middle East respiratory syndrome ; Neuropeptides ; Peptidase ; Peptides ; Peptidyl-dipeptidase A ; Proteins ; Respiratory diseases ; Respiratory distress syndrome ; Review ; Reviews ; Roles ; SARS-CoV-2 - physiology ; Severe acute respiratory syndrome coronavirus 2 ; Virus Internalization</subject><ispartof>Journal of cellular and molecular medicine, 2020-09, Vol.24 (18), p.10274-10278</ispartof><rights>2020 The Authors. published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd</rights><rights>2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.</rights><rights>2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5044-7d2a8f52d6fc32b80efc53b92fd9197b806910779bf1a1385f3fb90b34f9a7d23</citedby><cites>FETCH-LOGICAL-c5044-7d2a8f52d6fc32b80efc53b92fd9197b806910779bf1a1385f3fb90b34f9a7d23</cites><orcidid>0000-0002-9774-3980 ; 0000-0001-5080-9383</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521316/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521316/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,1417,11562,27924,27925,45574,45575,46052,46476,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32713161$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Du, Hengzhi</creatorcontrib><creatorcontrib>Wang, Dao Wen</creatorcontrib><creatorcontrib>Chen, Chen</creatorcontrib><title>The potential effects of DPP‐4 inhibitors on cardiovascular system in COVID‐19 patients</title><title>Journal of cellular and molecular medicine</title><addtitle>J Cell Mol Med</addtitle><description>With the outbreak of a new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the public healthcare systems are facing great challenges. Coronavirus disease 2019 (COVID‐19) could develop into severe pneumonia, acute respiratory distress syndrome and multi‐organ failure. Remarkably, in addition to the respiratory symptoms, some COVID‐19 patients also suffer from cardiovascular injuries. Dipeptidyl peptidase‐4 (DPP‐4) is a ubiquitous glycoprotein which could act both as a cell membrane‐bound protein and a soluble enzymatic protein after cleavage and release into the circulation. Despite angiotensin‐converting enzyme 2 (ACE2), the recently recognized receptor of SARS‐CoV and SARS‐CoV‐2, which facilitated their entries into the host, DPP‐4 has been identified as the receptor of middle east respiratory syndrome coronavirus (MERS‐CoV). In the current review, we discussed the potential roles of DPP‐4 in COVID‐19 and the possible effects of DPP‐4 inhibitors on cardiovascular system in patients with COVID‐19.</description><subject>ACE2</subject><subject>Angiotensin</subject><subject>Angiotensin-converting enzyme 2</subject><subject>Atherosclerosis</subject><subject>Binding sites</subject><subject>Cardiomyocytes</subject><subject>Cardiovascular Diseases - enzymology</subject><subject>Cardiovascular Diseases - virology</subject><subject>Cardiovascular system</subject><subject>Cell membranes</subject><subject>Chemokines</subject><subject>Coronaviridae</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 Drug Treatment</subject><subject>Cytokines</subject><subject>Diabetes</subject><subject>Dipeptidyl Peptidase 4 - metabolism</subject><subject>Dipeptidyl-peptidase IV</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - pharmacology</subject><subject>DPP‐4 inhibitors</subject><subject>Enzymes</subject><subject>Glucagon</subject><subject>Glycoproteins</subject><subject>Growth factors</subject><subject>Heart</subject><subject>Homeostasis</subject><subject>Hormones</subject><subject>Host-Pathogen Interactions</subject><subject>Humans</subject><subject>Infections</subject><subject>Inflammation</subject><subject>Kinases</subject><subject>Membrane proteins</subject><subject>Middle East respiratory syndrome</subject><subject>Neuropeptides</subject><subject>Peptidase</subject><subject>Peptides</subject><subject>Peptidyl-dipeptidase A</subject><subject>Proteins</subject><subject>Respiratory diseases</subject><subject>Respiratory distress syndrome</subject><subject>Review</subject><subject>Reviews</subject><subject>Roles</subject><subject>SARS-CoV-2 - physiology</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Virus Internalization</subject><issn>1582-1838</issn><issn>1582-4934</issn><issn>1582-4934</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kbtuFDEUhi1EREKg4QGQJRqEtInvlwYJbbgkSpQUgYbC8nhs1quZ8caeCdqOR-AZeRK87CYCirixdfz5s49_AF5gdITrOF66vj_CXEj2CBxgrsiMacoe79ZYUbUPnpayRIgKTPUTsE-JxBQLfAC-Xi88XKXRD2O0HfQheDcWmAI8ubr69eMng3FYxCaOKdfqAJ3NbUy3tripsxmWdRl9Xxk4v_xyelIPYA1XdozVV56BvWC74p_v5kPw-cP76_mn2fnlx9P5u_OZ44ixmWyJVYGTVgRHSaOQD47TRpPQaqxlLQiNkZS6CdhiqnigodGooSxoWw_TQ_B2611NTe9bV-_OtjOrHHub1ybZaP7dGeLCfEu3RnKy-YYqeL0T5HQz-TKaPhbnu84OPk3FEEYkx1ohWdFX_6HLNOWhtmeIlJQzJpl4kGJMCKKEopV6s6VcTqVkH-6fjJHZJGs2yZo_yVb45d9N3qN3UVYAb4HvsfPrB1TmbH5xsZX-Bm0urvg</recordid><startdate>202009</startdate><enddate>202009</enddate><creator>Du, Hengzhi</creator><creator>Wang, Dao Wen</creator><creator>Chen, Chen</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9774-3980</orcidid><orcidid>https://orcid.org/0000-0001-5080-9383</orcidid></search><sort><creationdate>202009</creationdate><title>The potential effects of DPP‐4 inhibitors on cardiovascular system in COVID‐19 patients</title><author>Du, Hengzhi ; Wang, Dao Wen ; Chen, Chen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5044-7d2a8f52d6fc32b80efc53b92fd9197b806910779bf1a1385f3fb90b34f9a7d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>ACE2</topic><topic>Angiotensin</topic><topic>Angiotensin-converting enzyme 2</topic><topic>Atherosclerosis</topic><topic>Binding sites</topic><topic>Cardiomyocytes</topic><topic>Cardiovascular Diseases - enzymology</topic><topic>Cardiovascular Diseases - virology</topic><topic>Cardiovascular system</topic><topic>Cell membranes</topic><topic>Chemokines</topic><topic>Coronaviridae</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 Drug Treatment</topic><topic>Cytokines</topic><topic>Diabetes</topic><topic>Dipeptidyl Peptidase 4 - metabolism</topic><topic>Dipeptidyl-peptidase IV</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - pharmacology</topic><topic>DPP‐4 inhibitors</topic><topic>Enzymes</topic><topic>Glucagon</topic><topic>Glycoproteins</topic><topic>Growth factors</topic><topic>Heart</topic><topic>Homeostasis</topic><topic>Hormones</topic><topic>Host-Pathogen Interactions</topic><topic>Humans</topic><topic>Infections</topic><topic>Inflammation</topic><topic>Kinases</topic><topic>Membrane proteins</topic><topic>Middle East respiratory syndrome</topic><topic>Neuropeptides</topic><topic>Peptidase</topic><topic>Peptides</topic><topic>Peptidyl-dipeptidase A</topic><topic>Proteins</topic><topic>Respiratory diseases</topic><topic>Respiratory distress syndrome</topic><topic>Review</topic><topic>Reviews</topic><topic>Roles</topic><topic>SARS-CoV-2 - physiology</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Virus Internalization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Du, Hengzhi</creatorcontrib><creatorcontrib>Wang, Dao Wen</creatorcontrib><creatorcontrib>Chen, Chen</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of cellular and molecular medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Du, Hengzhi</au><au>Wang, Dao Wen</au><au>Chen, Chen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The potential effects of DPP‐4 inhibitors on cardiovascular system in COVID‐19 patients</atitle><jtitle>Journal of cellular and molecular medicine</jtitle><addtitle>J Cell Mol Med</addtitle><date>2020-09</date><risdate>2020</risdate><volume>24</volume><issue>18</issue><spage>10274</spage><epage>10278</epage><pages>10274-10278</pages><issn>1582-1838</issn><issn>1582-4934</issn><eissn>1582-4934</eissn><abstract>With the outbreak of a new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the public healthcare systems are facing great challenges. Coronavirus disease 2019 (COVID‐19) could develop into severe pneumonia, acute respiratory distress syndrome and multi‐organ failure. Remarkably, in addition to the respiratory symptoms, some COVID‐19 patients also suffer from cardiovascular injuries. Dipeptidyl peptidase‐4 (DPP‐4) is a ubiquitous glycoprotein which could act both as a cell membrane‐bound protein and a soluble enzymatic protein after cleavage and release into the circulation. Despite angiotensin‐converting enzyme 2 (ACE2), the recently recognized receptor of SARS‐CoV and SARS‐CoV‐2, which facilitated their entries into the host, DPP‐4 has been identified as the receptor of middle east respiratory syndrome coronavirus (MERS‐CoV). In the current review, we discussed the potential roles of DPP‐4 in COVID‐19 and the possible effects of DPP‐4 inhibitors on cardiovascular system in patients with COVID‐19.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>32713161</pmid><doi>10.1111/jcmm.15674</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-9774-3980</orcidid><orcidid>https://orcid.org/0000-0001-5080-9383</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1582-1838 |
| ispartof | Journal of cellular and molecular medicine, 2020-09, Vol.24 (18), p.10274-10278 |
| issn | 1582-1838 1582-4934 1582-4934 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7521316 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); PubMed Central |
| subjects | ACE2 Angiotensin Angiotensin-converting enzyme 2 Atherosclerosis Binding sites Cardiomyocytes Cardiovascular Diseases - enzymology Cardiovascular Diseases - virology Cardiovascular system Cell membranes Chemokines Coronaviridae Coronaviruses COVID-19 COVID-19 Drug Treatment Cytokines Diabetes Dipeptidyl Peptidase 4 - metabolism Dipeptidyl-peptidase IV Dipeptidyl-Peptidase IV Inhibitors - pharmacology DPP‐4 inhibitors Enzymes Glucagon Glycoproteins Growth factors Heart Homeostasis Hormones Host-Pathogen Interactions Humans Infections Inflammation Kinases Membrane proteins Middle East respiratory syndrome Neuropeptides Peptidase Peptides Peptidyl-dipeptidase A Proteins Respiratory diseases Respiratory distress syndrome Review Reviews Roles SARS-CoV-2 - physiology Severe acute respiratory syndrome coronavirus 2 Virus Internalization |
| title | The potential effects of DPP‐4 inhibitors on cardiovascular system in COVID‐19 patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T22%3A02%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20potential%20effects%20of%20DPP%E2%80%904%20inhibitors%20on%20cardiovascular%20system%20in%20COVID%E2%80%9019%20patients&rft.jtitle=Journal%20of%20cellular%20and%20molecular%20medicine&rft.au=Du,%20Hengzhi&rft.date=2020-09&rft.volume=24&rft.issue=18&rft.spage=10274&rft.epage=10278&rft.pages=10274-10278&rft.issn=1582-1838&rft.eissn=1582-4934&rft_id=info:doi/10.1111/jcmm.15674&rft_dat=%3Cproquest_pubme%3E2773544746%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2446628683&rft_id=info:pmid/32713161&rfr_iscdi=true |